Posted by Michael Wonder on 27 Feb 2019
Korea’s 30th novel drug K-Cab to get insurance benefit from March
27 February 2019 - Korea’s 30th novel medicine K-Cab Tab. (tegoprazan) will receive insurance coverage, eight months after winning approval, the government said.
The gastric acid inhibitor will be reimbursable from March 1.
The Ministry of Health and Welfare’s health insurance policy review committee set the price of K-Cab Tab. 50mg at 1,300 won ($1.16) per pill on Tuesday.
